{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:56:41Z","timestamp":1773338201015,"version":"3.50.1"},"reference-count":21,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2006,6,6]],"date-time":"2006-06-06T00:00:00Z","timestamp":1149552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2006,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Early\u2010stage (IA, IB, IIA) mycosis fungoides (MF) has long been treated with various agents including topical potent steroids, nitrogen mustard, carmustine, oral psoralen plus UVA (PUVA), broadband UVB, electron\u2010beam radiotherapy, interferon\u2010\u03b1 and retinoids. However, each of these modalities is associated with various side\u2010effects. Narrowband UVB (NB\u2010UVB) therapy has the same effect but is safer to use than the other methods.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> Our purpose in this prospective study was to determine the effects of NB\u2010UVB in early\u2010stage MF both clinically and histopathologically.<\/jats:p><jats:p><jats:bold>Materials and methods\u2002<\/jats:bold> Twenty\u2010three patients (20 men, three women, aged 27\u201378\u00a0years) with clinically and histologically confirmed MF were enrolled. Patients received NB\u2010UVB therapy three times a week. Clinical and histological responses, cumulative doses, total number of treatments, side\u2010effects and duration of remission period were noted.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Six patients had stage\u00a0IA MF, 15 patients stage\u00a0IB and two patients stage\u00a0IIA. Eighteen patients had patch stage and five patients had plaque stage histopathologically. All of the patients in the patch group had a complete response (CR). In the plaque group, three patients (60%) had a CR and two\u00a0(40%) had partial (PR) or no clinical response (NR). The clinical response between patch and plaque groups was statistically significant. Regarding the histopathological findings, 17 (94.4%) had complete clearing and only one (5.6%) patient had a partial improvement in the patch group. In the plaque group, one\u00a0(20%) patient had complete clearing and four\u00a0(80%) patients had partial or no improvement. The difference between the two groups was statistically significant. In the patch group, the mean cumulative dose was 90.15\u00a0J\/cm<jats:sup>2<\/jats:sup> and the mean number of treatments was 35.33. In the plaque group, the mean cumulative dose was 90.67\u00a0J\/cm<jats:sup>2<\/jats:sup> and the mean total number of treatments was 39.40. The differences were not statistically significant, either between the mean cumulative dose or the mean number of treatments. The mean duration of follow\u2010up was 10.87\u00a0months (range 1\u201325\u00a0months). Only one of the patients had a relapse.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> NB\u2010UVB therapy for patients with early\u2010stage MF is an effective and safe treatment with the effect lasting for months. We suggest that clinical clearance correlates with histological improvement except for patients in the plaque stage.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2006.01635.x","type":"journal-article","created":{"date-parts":[[2006,6,6]],"date-time":"2006-06-06T10:29:57Z","timestamp":1149589797000},"page":"804-809","source":"Crossref","is-referenced-by-count":57,"title":["Narrowband UVB phototherapy for early\u2010stage mycosis fungoides: evaluation of clinical and histopathological changes"],"prefix":"10.1111","volume":"20","author":[{"given":"G","family":"G\u00f6kdemir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Barutcuo\u01e7lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Sak\u0131z","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"K\u00f6\u015fl\u00fc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,6,6]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2004.00937.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2003.05698.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2340\/0001555576475478","article-title":"PUVA in early mycosis fungoides may give long\u2010term remission and delay extracutaneous spread","volume":"76","author":"Roupe G","year":"1996","journal-title":"Acta Derm Venereol (Stockh)"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120911"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.449"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.123482"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2003.01644.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.05.010"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0781.2003.00039.x"},{"key":"e_1_2_5_11_2","first-page":"1537","volume-title":"Fitzpatrick's Dermatology in General Medicine","author":"Latkowski JA","year":"2003"},{"key":"e_1_2_5_12_2","first-page":"12.1","volume-title":"Pathology of the Skin","author":"McKee P","year":"1996"},{"key":"e_1_2_5_13_2","first-page":"105","volume-title":"Phototherapy Treatment Protocols","author":"Zanolli MD","year":"2000"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.131.9.1081"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.80"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02898.x"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.01.047"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.135.11.1377"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.6.748"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2003.tb00479.x"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1992.01680170063007"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(93)70155-M"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2006.01635.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2006.01635.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T17:39:43Z","timestamp":1697045983000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2006.01635.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,6]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1111\/j.1468-3083.2006.01635.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2006.01635.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,6]]}}}